Biotech

All Articles

Ideaya bags alternative on Biocytogen bispecific ADC in $400M package

.Ideaya Biosciences is actually wagering $400 million in biobucks that a bispecific antibody-drug co...

Takeda takes $140M reduction on neglected epilepsy medicine, boasts FDA run

.We currently understand that Takeda is intending to find a course to the FDA for epilepsy medicine ...

VBI Injections declare bankruptcy, finds asset purchase

.Immunology biotech VBI Injections is diverting alarmingly near the point of no return, along with p...

Celldex anti-cKIT antitoxin decrease hives in another phase 2 research

.It's difficult to muscle mass in on an area as very competitive as immunology, yet Celldex Therapeu...

Boehringer provides to $1.3 B for gate prevention biotech

.Boehringer Ingelheim is actually offering up to $1.3 billion for Nerio Therapeutics and also a prec...

Ventyx's last resort for inflamed med ends in Crohn's failure

.Ventyx Biosciences' Crohn's disease medicine performed certainly not help individuals obtain remiss...

Cognition's phase 2 SHINE information tarnish Alzheimer's prospect

.Knowledge Therapies' stage 2 sparkle test has actually taken some of the gloss off the Alzheimer's ...

BMS centers bispecific months after submitting to function period 3 trial

.Bristol Myers Squibb has actually possessed a whiplash change of mind on its own BCMA bispecific T-...

Charles Baum takes control of Terremoto as CEO

.Charles Baum, M.D., Ph.D., who looked after Mirati Therapeutics' $ 5.8 billion sale to Bristol Myer...

Asarina to shut after efforts to partner Tourette's drug fall short

.After connecting to much more than 200 firms to companion a Tourette syndrome therapy that showed t...